<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1799">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04401202</url>
  </required_header>
  <id_info>
    <org_study_id>266-20</org_study_id>
    <nct_id>NCT04401202</nct_id>
  </id_info>
  <brief_title>Nigella Sativa in COVID-19</brief_title>
  <official_title>Effects of Nigella Sativa as a Treatment of Patients With Upper Respiratory Tract Infection Caused by SARS-coronavirus-2: a Prospective, Randomized, Open-label, Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Abdulaziz University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Abdulaziz University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Natural products with immunomodulation and antiviral activity showed a promising improvement
      in the outcomes of some viral infectious diseases both in preclinical and primitive clinical
      studies. The aim of this study is to utilize Saudi FDA licensed Nigella sativa (NS) seed oil
      towards improving disease outcomes in hospitalized adult patients diagnosed with COVID-19.
      The study will be a prospective, open-label, non-randomized controlled pilot trial. Patients
      will be supplemented (add-on) with one capsule of black seed oil twice daily for 10 days. The
      primary outcome will be the proportion of patients who clinically recovered on day 14. The
      secondary outcomes will be clinical parameters and routine laboratory tests. If encouraging
      outcomes occurred, NS supplementation may be recommended as an add-on to standard care
      protocol to enhance the recovery from COVID-19 disease in the current emerging situation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, open-label, controlled clinical study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who are clinically recovered</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to full clinical recovery or progression to pneumonia or hypoxia</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization of chest radiograph</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complications</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>NS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nigella sativa</intervention_name>
    <description>Black seed oil in 500 mg capsules</description>
    <arm_group_label>NS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with COVID19 upper respiratory tract infection with no evidence of pneumonia

          -  Adult (18 Years and above)

          -  Written informed consent prior to initiation of any study procedures by the patient
             (or legally authorized representative).

          -  Understands and agrees to comply with planned study procedures.

          -  Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by
             polymerase chain reaction (PCR) available at KAUH.

        Exclusion Criteria:

          -  Patients with pneumonia or severe illness requiring admission to ICU.

          -  Severe chronic kidney disease (i.e. estimated glomerular filtration rate (eGFR) &lt; 30)
             or end stage renal disease requiring dialysis

          -  Sever chronic liver disease (Alanine transaminase/aspartate transaminase (ALT/AST) &gt; 5
             times the upper limit of normal).

          -  Pregnancy or breast feeding.

          -  Anticipated transfer to another hospital which is not a study site within 72 hours.

          -  Allergy to any study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Abdulrahman Koshak, Dr</last_name>
    <phone>6400000</phone>
    <email>aekoshak@kau.edu.sa</email>
  </overall_contact>
  <location>
    <facility>
      <name>King Abdulaziz University Hospital</name>
      <address>
        <city>Jeddah</city>
        <zip>21589</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdulrahman Koshak, Dr</last_name>
      <phone>6400000</phone>
      <email>aekoshak@kau.edu.sa</email>
    </contact>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 21, 2020</study_first_submitted>
  <study_first_submitted_qc>May 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Abdulaziz University</investigator_affiliation>
    <investigator_full_name>Dr Abdulrahman E. Koshak</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Nigella sativa</keyword>
  <keyword>Herbal</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

